A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
This important study is looking for babies and toddlers (up to two years old) with achondroplasia to test a new medicine called Navepegritide (also known as TransCon CNP). Achondroplasia is a condition that affects how bones grow. For one year, some children will receive the new medicine through a weekly injection, while others will get a placebo, which is a dummy medicine with no active ingredients. The main goal is to find out if Navepegritide is safe and if it helps children grow better than those who receive the placebo. Doctors will carefully monitor the children throughout the study to understand the medicine's effects.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about a new medicine called Navepegritide (sometimes called TransCon CNP) for very young children, specifically babies and toddlers up to two years old, who have a condition called achondroplasia. Achondroplasia is a genetic condition that affects how bones grow, leading to shorter limbs. The researchers want to see if this new medicine can help improve growth and if it is safe for these young children.
To do this, some children in the study will receive the new medicine, while others will receive a placebo. A placebo looks just like the real medicine but contains no active ingredients; it helps researchers fairly compare the effects of the new medicine. Neither the families nor the doctors will know who is getting which treatment until the study is over. This is called a 'double-blind' study and helps ensure the results are as fair and unbiased as possible. The medicine or placebo will be given as an injection under the skin once a week for a year.
The study is in 'Phase 2,' which means it's one of the earlier stages of testing. This phase focuses on checking the safety of the medicine and getting an idea of how well it works. The information gathered from this study will be crucial in deciding if the medicine should be tested in more children in the future.
النقاط الرئيسية
- This study tests a new medicine for babies and toddlers with achondroplasia.
- It aims to check the medicine's safety and how it affects growth.
- Children will receive weekly injections of either the medicine or a placebo for one year.
- Regular clinic visits and health checks are part of the study.
- المشاركة طوعية، ويمكنك الانسحاب في أي وقت.
- The study is in an earlier stage of research (Phase 2).
من قد يكون مؤهلاً؟
To join this study, your child must have achondroplasia, which has been confirmed by a genetic test. They need to be under two years old when they start the study. Also, you as their parent or guardian must be willing to give regular injections at home and attend all necessary appointments.
There are some reasons why a child might not be able to join. For example, if they were born very prematurely, or if they have a severe allergic reaction to certain ingredients in the medicine. Children whose achondroplasia is due to a specific genetic type called 'homozygous' will also not be able to participate. Also, if a child is expected to need surgery during the study period, they generally won't be able to join.
The study team will check your child's medical history, conduct examinations, and do some tests to make sure it's safe for them to take part and that they meet all the study requirements.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل طفلك أقل من سنتين؟
- Does your child have achondroplasia confirmed by a genetic test?
- Are you able and willing to administer weekly injections?
- هل تستطيع حضور المواعيد المنتظمة في العيادة؟
- Does your child not have a severe allergy to the study medicine's ingredients?
ماذا يتضمن المشاركة؟
If your child joins this study, they will receive either the study medicine (Navepegritide) or a placebo, given as an injection under the skin once a week for 52 weeks (one year). You, as the parent or caregiver, will be taught how to give these injections at home. Throughout the year, your child will need to have regular check-ups at the study clinic. These visits will involve physical examinations, taking measurements of your child's growth, and some blood tests to check their health and how the medicine is affecting them. There will also be some scans, like X-rays, to look at their bones. After the year of treatment, there will be follow-up visits to continue monitoring your child's health and development. The total duration of active treatment is one year, with follow-up appointments extending beyond that.
المخاطر والفوائد المحتملة
المواقع (18)
- Ascendis Investigational Siteالرمز البريدي المؤكدSaint Paul, United States· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدهيوستن، الولايات المتحدة· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدماديسون، الولايات المتحدة· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدباركفيل، أستراليا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدلينز، النمسا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدمونتريال، كندا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدكوبنهاغن، الدنمارك· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدهلسنكي، فنلندا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدباريس، فرنسا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدبرلين، ألمانيا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكدكولونيا، ألمانيا· التوظيف
- Ascendis Investigational Siteالرمز البريدي المؤكددبلن، أيرلندا· التوظيف
أسئلة شائعة
What is achondroplasia?
Achondroplasia is a genetic condition that affects how bones grow, particularly in the arms and legs, leading to a shorter stature.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' medicine that looks like the real treatment but contains no active ingredients. It helps researchers fairly compare the effects of the new medicine.
هل سيحصل طفلي بالتأكيد على الدواء الجديد؟
No, there's a 2 in 3 chance your child will receive the new medicine and a 1 in 3 chance they will receive the placebo. Neither you nor the doctors will know which until the study ends.
كم من الوقت سيبقى طفلي في الدراسة؟
Your child will receive the study treatment (or placebo) for one year, with additional follow-up visits after that period.
Can I stop my child's participation at any time?
Yes, you have the right to withdraw your child from the study at any point, and it will not affect their future medical care.
كيفية معرفة المزيد
Ascendis Registry Inquiries
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.